BackKeros Therapeutics Overview
Keros Therapeutics Inc

Keros Therapeutics Target Price

Analysts' average 12-month price target for Keros Therapeutics is $20.

Get informed when a big investor buys or sells

+ Follow

Share Price

$11.4

Average Target Price

$20.3378.4% upside

3 analysts in the last 4 months

High: $23 | Low: $18

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Wells FargoBenjamin Burnett$1857.9% upsideOpen
2026-08-04H.C. WainwrightAndrew Fein$2075.4% upsideOpen
2026-08-04Leerink Partners$23101.8% upsideOpen
2024-11-05JefferiesKelly Shi$107838.6% upsideOpen
2024-11-05Truist FinancialSrikripa Devarakonda$100777.2% upsideOpen
2024-09-23GuggenheimVamil Divan$96742.1% upsideOpen
2024-06-18Piper SandlerJoseph Catanzaro$105821.1% upsideOpen
2022-12-13BTIG$105821.1% upsideOpen
2022-07-27BTIGJulian Harrison$80601.8% upsideOpen
2022-05-18Piper SandlerJoseph Catanzaro$120952.6% upsideOpen

Keros Therapeutics (KROS) FAQ

Keros Therapeutics (KROS) currently reports a target price of $20. Use the charts on this page to explore Keros Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Keros Therapeutics is $20, about 78.4% upside from the current share price of $11.4. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $20, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Keros Therapeutics, and consider following KROS for alerts when major investors trade the stock.

Keros Therapeutics is classified in the Healthcare sector. On target price, it currently shows $20. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KROS with unrelated industries.